Drug news
Macrilen (macimorelin) fails Phase III trial for treatment of growth hormone deficiency.-Aeterna Zentaris Inc.
Aeterna Zentaris Inc. has announced that the confirmatory Phase III clinical trial of Macrilen (macimorelin) failed to achieve its objective of validating a single oral dose of macimorelin for the evaluation of growth hormone deficiency in adults , using the insulin tolerance test as a comparator. The Company is evaluating the outcome of the trial and will determine in the near future whether it will continue with the development of Macrilen.